• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, November 16, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Trial Protocol Tests Empagliflozin in Duchenne Cardiomyopathy

by
November 8, 2026
in Health
Reading Time: 4 mins read
0
Trial Protocol Tests Empagliflozin in Duchenne Cardiomyopathy

Trial Protocol Tests Empagliflozin in Duchenne Cardiomyopathy

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Researchers have published a detailed protocol for the REDMeD trial, a single-arm, single-centre, open-label phase 2a study designed to evaluate the pharmacokinetics, safety, and proof-of-concept efficacy of empagliflozin in children and adolescents with Duchenne muscular dystrophy-associated cardiomyopathy. The study, registered under NCT06643442 and ISRCTN 12497973, aims to address a critical gap in pediatric heart failure treatment by repurposing a drug that has shown significant benefits in adult populations. Duchenne muscular dystrophy is a life-limiting hereditary condition characterized by progressive muscle wasting, where heart failure has become the principal cause of death, often outpacing respiratory complications as the primary life-limiting factor.

The rationale for this trial stems from the success of sodium-glucose cotransporter type 2 (SGLT2) inhibitors in adult heart failure management. Since 2021, international guidelines have recommended adding dapagliflozin or empagliflozin to standard therapies such as ACE inhibitors, beta-blockers, and mineralocorticoid receptor antagonists for adults with heart failure with reduced ejection fraction. These medications have been shown to reduce a composite outcome of cardiovascular death or worsening heart failure by 25–26% on top of optimal medical therapy. However, despite convincing preclinical evidence suggesting benefits for both skeletal and cardiac myocytes in Duchenne muscular dystrophy, specific clinical data for this pediatric population have been lacking until now.

The REDMeD trial will recruit 12 participants aged 6 to 18 years who have a confirmed diagnosis of Duchenne muscular dystrophy-associated cardiomyopathy and are currently on stable heart failure medication. Eligibility requires that participants can swallow commercially available tablets, which is why the lower age limit is set at 6 years. The primary objective of the study is to describe the pharmacokinetic behavior of empagliflozin in this specific population. This is crucial because Duchenne muscular dystrophy involves altered body composition, reduced muscle mass, and potential renal disease, all of which may affect how the drug is processed in the body.

Participants will take oral empagliflozin 10 mg once daily for a period of six months. The study design includes a whole-day stay at the first visit for intensive pharmacokinetic evaluation, followed by follow-up visits at 1 week, 6 weeks, 3 months, and 6 months. An additional end-study visit will occur 2 to 12 weeks after the trial completion. This structured approach allows for the collection of blood samples at specific time points to model the drug’s concentration in the body, using a non-linear mixed effects modelling approach that leverages prior knowledge from adult studies and developmental pharmacokinetics.

Beyond pharmacokinetics, the trial aims to assess the ease of swallowing the medication, monitor safety, and explore potential efficacy markers. Secondary endpoints include clinical parameters such as heart rate and blood pressure, biochemical markers like NT-proBNP and renal function, and imaging results from echocardiography and cardiac magnetic resonance imaging. The study will also utilize whole-body bioimpedance spectroscopy to explore the differential role of intra- and extracellular body fluid compartments, providing insight into the mechanisms of cardiovascular protection offered by SGLT2 inhibitors.

The study design incorporates a translational approach to address common pitfalls in previous pediatric heart failure trials, such as suboptimal dosing, inappropriate formulations, or inadequate endpoints. By using model-based simulations, the researchers determined that a sample size of 12 patients is sufficient to ensure adequate precision of the pharmacokinetic parameters of interest. This efficient design minimizes the burden on participants and their families while maximizing the quality of the generated information, a critical consideration given the recruitment difficulties often associated with pediatric trials.

Patient and public involvement played a significant role in shaping the trial protocol. A survey was conducted among eight patients and families to assess the relevance of the study, the clarity of information, and the feasibility of the schedule. All participants felt that pediatric heart failure drug studies were important, with a mean score of 4.8 out of 5 for their overall feeling about the REDMeD trial. Seven out of eight participants indicated they would have considered study participation if approached. Feedback from families led to practical improvements, such as allowing patients to spend the day in a clinical trial unit with playrooms rather than strictly in their own rooms, and providing travel reimbursement and certificates for school absences.

Safety monitoring is a key component of the trial, involving the assessment of symptoms, signs, laboratory results, and 12-lead ECGs at multiple visits. Exclusion criteria are strictly defined to ensure participant safety, including the exclusion of patients with type 1 or type 2 diabetes, body weight less than 15 kg, estimated glomerular filtration rate below 45 mL/min/1.73 m², and sustained or symptomatic arrhythmia.

The trial acknowledges several limitations, primarily due to its small sample size. While the study will provide valuable insight into the pharmacokinetics and middle-term safety profile of empagliflozin, it does not provide the basis for establishing definitive efficacy. The single-arm design means that the researchers may need to collect external control data to perform a model-based evaluation of pharmacodynamics and efficacy in a subsequent step. Additionally, the small sample size will not allow for subgroup analyses, such as those based on age or disease severity.

Empagliflozin is already licensed for adults with symptomatic chronic heart failure, chronic kidney disease, and type 2 diabetes, as well as for adolescents aged 10 to 18 with type 2 diabetes. Current consensus for Duchenne muscular dystrophy-associated cardiomyopathy recommends considering SGLT2 inhibitors if left ventricular function deteriorates despite appropriate therapy. The REDMeD trial builds on this foundation by providing the necessary pharmacokinetic data to inform dose selection and identify efficacy markers that can be used in future, larger efficacy trials. The results are expected to be communicated in a patient-friendly format to study participants and patient associations, in addition to publication in peer-reviewed journals and presentation at scientific congresses.

The study was reviewed and approved by the London—Hampstead Research Ethics Committee and the UK Medicines and Healthcare products Regulatory Agency. Informed consent will be sought from participants older than 16, while parents or guardians will provide consent for younger participants, with the children providing assent.

Subject of Research: Protocol for a pharmacokinetics, safety, and proof-of-concept trial of empagliflozin in pediatric Duchenne muscular dystrophy-associated cardiomyopathy.

Article Title: Repurposing Empagliflozin for Duchenne Muscular Dystrophy-Associated Cardiomyopathy: Protocol for a Pharmacokinetics, Safety and Proof-of-Concept Trial in Children

Article References: Lava, S. A. G., Laurence, C., Mallory, J., Della Pasqua, O., Di Deo, A., Villa, C., Lang, S., Quail, M., & Burch, M. (2026). Repurposing Empagliflozin for Duchenne Muscular Dystrophy-Associated Cardiomyopathy: Protocol for a Pharmacokinetics, Safety and Proof-of-Concept Trial in Children. Cardiology and Therapy, 15(3), 503-514. https://doi.org/10.1007/s40119-026-00456-6

Image Credits: AI Generated

DOI: 10.1007/s40119-026-00456-6

Keywords: Duchenne muscular dystrophy, empagliflozin, cardiomyopathy, pharmacokinetics, pediatric heart failure, SGLT2 inhibitors, clinical trial protocol, drug repurposing, Repurposing, Duchenne, Muscular, Dystrophy-Associated

News Source: Ophelia Keating. (November 8, 2026). Trial Protocol Tests Empagliflozin in Duchenne Cardiomyopathy. Scienmag.

Tags: cardiomyopathyClinical Trial ProtocolDrug repurposingduchenneDuchenne muscular dystrophyDystrophy-AssociatedempagliflozinMuscularpediatric heart failurePharmacokineticsrepurposingSGLT2 inhibitors
Share12Tweet7Share2ShareShareShare1

Related Posts

Simulated Prosthesis Use Elevates Mental Demand and Prefrontal Brain Activation

Simulated Prosthesis Use Elevates Mental Demand and Prefrontal Brain Activation

November 16, 2026
Human Fetal Spleen Matrix Scaffold Shows Biocompatibility and Host Integration in Rats

Human Fetal Spleen Matrix Scaffold Shows Biocompatibility and Host Integration in Rats

November 16, 2026

Review Evaluates Herbal, MicroRNA, and Probiotic Experimental Therapies for Endometritis

November 16, 2026

Salmonella Lineage Crosses Poultry and Human Contacts in Urban Ghana Study

November 16, 2026

POPULAR NEWS

  • Maintenance BCG Reduces Bladder Cancer Progression When Patients Overcome Treatment Barriers

    Maintenance BCG Reduces Bladder Cancer Progression When Patients Overcome Treatment Barriers

    29 shares
    Share 12 Tweet 7
  • High-Avidity BCMA CAR T-Cell Therapy Shows High Efficacy in AL Amyloidosis

    29 shares
    Share 12 Tweet 7
  • Zero Mass Limit in Karch-Randall Gravity Yields Decoupled Massive Vector Theory

    29 shares
    Share 12 Tweet 7
  • Kenyan Smallholder Farmers Classify Diverse Pasture Species for Sustainable Dairy Production

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Simulated Prosthesis Use Elevates Mental Demand and Prefrontal Brain Activation

Cenobamate Reduced Refractory Seizures in Retrospective Brain Tumor Cohort Study

Machine Learning Model Simulates Solid Electrolyte Interphase Reactions in Lithium Batteries

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 87 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.